Evaluation of the Sphingolipid Metabolite S1P as a Novel Biomarker in Food Allergy

NCT01776489 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2015-12-11

No results posted yet for this study

Summary

Food allergies represent an increasing health concern in the industrialized countries and especially affect pediatric patients. In this population adverse reactions against food compounds can lead to anaphylactic reactions. Despite substantial research efforts, clinical markers predicting disease severity and symptoms are missing to date.

Recent studies have revealed that sphingolipids, especially sphingosine-1-phosphate (S1P), play an essential role in allergy. It was reported that asthmatic patients have higher S1P levels in bronchiallavage fluids after allergen challenge. First experimental studies revealed a correlation of S1P and the outcome of anaphylaxis. Furthermore, we have shown in our recent mouse study that S1P homeostasis is pivotal for food allergy induction and effector cell response. Therefore, it is the aim of the presented pilot project to evaluate whether S1P serum titers are altered in food allergic children and if the S1P levels correlate with the outcome of anaphylaxis during double blind placebo controlled food challenges (DBPCFCs).

Conditions

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Eva Untersmayr-Elsenhuber, MD, PhD · Medical University Vienna, Department of Pathophysiology and Allergy Research

Eligibility

Min Age
12 Months
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2017-01-31
Completion
2017-01-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01776489 on ClinicalTrials.gov